Lobbying Filing Details

Total Spending

$390,000

Activities

5

Lobbyists

2

Gov't Entities

14

Filing Information
Filing UUID:
145ae244-f2d7-48aa-9a67-2d78ffb338f1
Type:
Q4 - 4th Quarter - Report
Period:
2025 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 21, 2026 at 1:01 AM
Income:
$0
Expenses:
$390,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Jason D. Kaune, Attorney & Agent for Filer
Registrant
BIOMARIN PHARMACEUTICAL INC.

Develops and commercializes biopharmaceuticals.

San Rafael, California
Client
BIOMARIN PHARMACEUTICAL INC.
California, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

H.R.5371: CONTINUING APPROPRIATIONS, ARGICULTURE, LEGISLATIVE BRANCH, MILITARY CONSTRUCTION AND VETERANS AFFAIRS, AND EXTENSIONS ACT, 2026; PROVISIONS RELATED TO JOINT EXPLANTATORY STATEMENT, DIV. B

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (5)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Executive Office of the President (EOP)
  • Health & Human Services, Dept of (HHS)
  • Food & Drug Administration (FDA)
Activity 2
Health Issues

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Lobbyists (2)
  • KATHRYN LOWELL
  • JOHN EDWARD GREISSING
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Commerce, Dept of (DOC)
Activity 5
Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.